Literature DB >> 25200433

Establishment of a novel triple-transgenic mouse: conditionally and liver-specifically expressing hepatitis C virus NS3/4A protease.

H Y Lan1, Y Zhao, J Yang, M N Sun, Y F Lei, M Yao, X J Huang, J M Zhang, Z K Xu, X Lü, W Yin.   

Abstract

It is well known that NS3/4A protein plays crucial roles in the hepatitis C virus (HCV) replication. NS3/4A protein also results to virus-mediated immune evasion and persistence of infection through the interaction with host proteins. However, the lack of a suitable animal model hampers studies of HCV NS3/4A protein interaction with host proteins, which impacts immunopathology due to infection. Here, transgenic vector containing transcriptional regulation and Fluc reporter gene was constructed to conditionally express NS3/4A protein under the dual control of Tet-On regulatory system and Cre/LoxP gene-knockout system. NS3/4A transgenic founder mice were continuously crossed with Lap transgenic mice expressing reverse tetracycline-controlled transcriptional activator (rtTA), the NS3/4A/Lap double transgenic mouse lines with liver-specifically and conditionally expressing reporter (luciferase Fluc) under control of Tet-On system were established. The NS3/4A/Lap double transgenic mouse are mated with Lap/LC-1 double transgenic mouse with liver-specifically and conditionally expressing Cre recombinase under control of Tet-On system, NS3/4A/Lap/LC-1 triple transgenic mouse were generated. In vivo bioluminescent imaging, western blotting and immunohistochemical staining (IHS) was used to confirm that NS3/4A protein was strictly expressed in the liver of Doxycycline-induced triple transgenic mice. The results show that we established a triple-transgenic mouse model conditionally expressing the HCV NS3/4A protein under strict control of the Tet-On regulatory system and Cre/loxP system. This novel transgenic mouse model expressing NS3/4A in a temporally and spatially-specific manner will be useful for studying interactions between HCV NS3/4A protein and the host, also for evaluating NS3/4A protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25200433     DOI: 10.1007/s11033-014-3621-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  26 in total

Review 1.  Failure of innate and adaptive immune responses in controlling hepatitis C virus infection.

Authors:  Robert Thimme; Marco Binder; Ralf Bartenschlager
Journal:  FEMS Microbiol Rev       Date:  2012-01-04       Impact factor: 16.408

Review 2.  Animal models for the study of hepatitis C virus infection and related liver disease.

Authors:  Jens Bukh
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 3.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

4.  A model for the mechanism of precise integration of a microinjected transgene.

Authors:  M McFarlane; J B Wilson
Journal:  Transgenic Res       Date:  1996-05       Impact factor: 2.788

Review 5.  Bioluminescence imaging: progress and applications.

Authors:  Christian E Badr; Bakhos A Tannous
Journal:  Trends Biotechnol       Date:  2011-07-23       Impact factor: 19.536

6.  Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.

Authors:  A Kistner; M Gossen; F Zimmermann; J Jerecic; C Ullmer; H Lübbert; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Generation of inducible hepatitis C virus transgenic mouse lines.

Authors:  Evelyn Ernst; Kai Schönig; Joachim J Bugert; Hendrik Bläker; Eberhard Pfaff; Wolfgang Stremmel; Jens Encke
Journal:  J Med Virol       Date:  2007-08       Impact factor: 2.327

8.  Luminescent imaging of beta-galactosidase activity in living subjects using sequential reporter-enzyme luminescence.

Authors:  Thomas S Wehrman; Georges von Degenfeld; Peter O Krutzik; Garry P Nolan; Helen M Blau
Journal:  Nat Methods       Date:  2006-04       Impact factor: 28.547

Review 9.  Cellular models for the screening and development of anti-hepatitis C virus agents.

Authors:  Claire Gondeau; Lydiane Pichard-Garcia; Patrick Maurel
Journal:  Pharmacol Ther       Date:  2009-06-23       Impact factor: 12.310

10.  Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection.

Authors:  Paul Y Kwo
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

View more
  1 in total

1.  Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity.

Authors:  Min Yao; Xin Lu; Yingfeng Lei; Jing Yang; Haiwei Zhao; Qinghua Qiao; Peijun Han; Zhikai Xu; Wen Yin
Journal:  PLoS One       Date:  2016-03-04       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.